Xiangxue Pharmaceutical (300147) — Financial Flexibility Index
Xiangxue Pharmaceutical (300147) has a Financial Flexibility Index of 0.01x as of September 2025. Free cash flow of CN¥81.38 Million (operating CF CN¥75.64 Million minus capex CN¥5.74 Million) represents 0% of total liabilities (CN¥6.27 Billion). Check 300147 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Xiangxue Pharmaceutical Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Xiangxue Pharmaceutical across 19 annual periods. See how liquid is Xiangxue Pharmaceutical's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Xiangxue Pharmaceutical (2007–2025)
Year-by-year free cash flow to debt coverage for Xiangxue Pharmaceutical. For the full company profile including market capitalisation, see 300147 stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.02x | CN¥161.15 Million | CN¥139.63 Million | CN¥6.70 Billion | ▲ +172.8% |
| 2024 | 0.01x | CN¥53.42 Million | CN¥18.17 Million | CN¥6.06 Billion | ▼ -83.5% |
| 2023 | 0.05x | CN¥319.48 Million | CN¥263.44 Million | CN¥5.97 Billion | ▼ -41.2% |
| 2022 | 0.09x | CN¥594.65 Million | CN¥227.38 Million | CN¥6.53 Billion | ▼ -15.4% |
| 2021 | 0.11x | CN¥820.30 Million | CN¥257.56 Million | CN¥7.62 Billion | ▼ -38.4% |
| 2020 | 0.17x | CN¥964.60 Million | CN¥257.18 Million | CN¥5.53 Billion | ▲ +2.1% |
| 2019 | 0.17x | CN¥744.11 Million | CN¥83.02 Million | CN¥4.35 Billion | ▲ +34.5% |
| 2018 | 0.13x | CN¥586.70 Million | CN¥91.24 Million | CN¥4.61 Billion | ▼ -20.4% |
| 2017 | 0.16x | CN¥887.40 Million | CN¥109.53 Million | CN¥5.56 Billion | ▼ -68.2% |
| 2016 | 0.50x | CN¥2.16 Billion | CN¥198.48 Million | CN¥4.30 Billion | ▲ +27.3% |
| 2015 | 0.39x | CN¥436.84 Million | CN¥159.89 Million | CN¥1.11 Billion | ▲ +65.6% |
| 2014 | 0.24x | CN¥409.43 Million | CN¥165.58 Million | CN¥1.72 Billion | ▼ -35.0% |
| 2013 | 0.37x | CN¥646.92 Million | CN¥328.37 Million | CN¥1.76 Billion | ▼ -3.6% |
| 2012 | 0.38x | CN¥537.03 Million | CN¥118.91 Million | CN¥1.41 Billion | ▼ -26.6% |
| 2011 | 0.52x | CN¥260.24 Million | CN¥29.55 Million | CN¥502.16 Million | ▲ +141.1% |
| 2010 | 0.21x | CN¥102.33 Million | CN¥45.47 Million | CN¥476.01 Million | ▼ -21.7% |
| 2009 | 0.27x | CN¥99.04 Million | CN¥46.19 Million | CN¥360.69 Million | ▼ -49.6% |
| 2008 | 0.54x | CN¥193.44 Million | CN¥55.72 Million | CN¥354.94 Million | ▼ -30.2% |
| 2007 | 0.78x | CN¥282.75 Million | CN¥138.02 Million | CN¥361.98 Million | — |